Noonan syndrome (NS) is an autosomal dominant disorder that can be difficult to diagnose. Growth retardation is a consistent feature, however, and although children are not typically growth hormone (GH) deficient, a minority may have suboptimal GH levels. An ongoing multicentre study examining the safety and efficacy of GH therapy in NS showed increases in height standard deviation scores (SDS; p < 0.0001) and height velocity (p < 0.0001) after 12 months of GH at pharmacological doses. There was no increase in mean maximal cardiac left ventricular wall thickness during the 12-month treatment period. Long-term follow-up data covering 3 years of GH therapy showed sustained increases in height SDS and height velocity compared with baseline (p < 0.02). Further large and appropriately controlled studies of high-quality design are essential to further our understanding of NS and to establish the long-term safety and efficacy of GH.

Keywords:
Noonan syndrome, Growth, Growth hormone, Cardiac features
1.
Noonan J, Ehmke DA: Associated non-cardiac malformations in children with congenital heart disease. J Pediatr 1963;63:468.
2.
Mendez HMM, Opitz JM: Noonan syndrome: A review. Am J Med Genet 1985;21:493–506.
3.
Allanson JE, Hall JG, Hughes HE, Preus M, Witt RD: Noonan syndrome. A changing phenotype. Am J Med Genet 1985;21:507–514.
4.
Allanson JE: Noonan syndrome. J Med Genet 1987;24:9–13.
5.
Sharland M, Burch M, McKenna WJ, Patton MA: A clinical study of Noonan syndrome. Arch Dis Child 1992;67:178–183.
6.
Sharland M, Taylor R, Patton MA, Jeffery S: Absence of linkage of Noonan syndrome to the neurofibromatosis type 1 locus. J Med Genet 1992;29:188–190.
7.
Caralis DG, Char F, Graber JD, Voigt GC: Delineation of multiple cardiac anomalies associated with Noonan syndrome in an adult and review of the literature. Johns Hopkins Med J 1974;134:346–353.
8.
Ranke MB: Turner and Noonan syndromes; in Kelnar CJH, Savage MO, Stirling HF, Saenger P (eds): Growth Disorders – Pathophysiology and Treatment. London, Chapman & Hall, 1998, pp 623–639.
9.
Jamieson CR, van der Burgt I, Brady AF, van Reen M, Elsawi MM, Hol F, Jeffery S, Patton MA, Mariman E: Mapping a gene for Noonan syndrome to the long arm of chromosome 12. Nat Genet 1994;8:357–360.
10.
van der Burgt I, Berends E, Lommen E, van Beersum S, Hamel B, Mariman E: Clinical and molecular studies in a large Dutch family with Noonan syndrome. Am J Med Genet 1994;53:187–191.
11.
Witt DR, Keena BA, Hall JG, Allanson JE: Growth curves for height in Noonan syndrome. Clin Genet 1986;30:150–153.
12.
Ranke M, Heidemann P, Knupfer C, Enders H, Schmaltz AA, Bierich JR: Noonan syndrome: Growth and clinical manifestations in 144 cases. Eur J Pediatr 1988;148:220–227.
13.
Spadoni GL, Bernardini S, Cianfarani S: Spontaneous growth hormone secretion in Noonan syndrome. Acta Paediatr Scand 1990(suppl 367):157.
14.
Ahmed ML, Foot AB, Edge JA, Lamkin VA, Savage MO, Dunger DB: Noonan’s syndrome: Abnormalities of the growth hormone/IGF-I axis and the response to treatment with human biosynthetic growth hormone. Acta Paediatr Scand 1991;80:446–450.
15.
Elders MJ, Char F: Possible etiologic mechanisms of the short stature in the Noonan syndrome. Birth Defects Orig Artic Ser 1976;12:127–133.
16.
Tanaka K, Sato A, Naito T, Kuramochi K, Itabashi H, Takemura Y: Noonan syndrome presenting with growth hormone neurosecretory dysfunction. Intern Med 1992;31:908–911.
17.
Cotterill AM, McKenna WJ, Brady AF, Sharland M, Elsawi M, Yamada M, Camacho-Hubner C, Kelnar CJ, Dunger DB, Patton MA, Savage MO: The short-term effects of growth hormone therapy on height velocity and cardiac ventricular wall thickness in children with Noonan’s syndrome. J Clin Endocrinol Metab 1996;81:2291–2297.
18.
Romano AA, Blethen SL, Dana K, Noto RA: Growth hormone treatment in Noonan syndrome: The National Cooperative Growth Study experience. J Pediatr 1996;128(suppl):18–21.
19.
Otten BJ: Short stature in Noonan syndrome: Demography and response to growth hormone treatment in the Kabi International Growth Study; in Ranke MB, Gunnarsson R (eds): Progress in Growth Hormone Therapy – 5 Years of KIGS. Mannheim, J und J Verlag, 1996, pp 206–215.
20.
Albertsson-Wikland K, Rosberg S, Isaksson O, Westphal O: Secretory pattern of growth hormone in children of differing growth rates. Acta Endocrinol (Copenh) 1983;103(suppl 256):72.
21.
Burch M, Sharland M, Shinebourne E, Smith G, Patton MA, McKenna W: Cardiologic abnormalities in Noonan syndrome: Phenotypic diagnosis and echocardiographic assessment of 118 patients. J Am Coll Cardiol 1993;22:1189–1192.
22.
Wilmshurst PT, Katritsis D: Restrictive and hypertrophic cardiomyopathies in Noonan syndrome: The overlap syndromes. Heart 1996;75:94–97.
23.
Burch M, Mann JM, Sharland M, Shinebourne EA, Patton MA, McKenna WJ: Myocardial disarray in Noonan syndrome. Br Heart J 1992;68:586–588.
24.
Cooke RA, Chambers JB, Curry PV: Noonan’s cardiomyopathy: A non-hypertrophic variant. Br Heart J 1994;71:561–565.
25.
Nishikawa T, Ishiyama S, Shimojo T, Takeda K, Kasajima T, Momma K: Hypertrophic cardiomyopathy in Noonan syndrome. Acta Paediatr Jpn 1996;38:91–98.
26.
Ishizawa A, Oho S, Dodo H, Katori T, Homma S: Cardiovascular abnormalities in Noonan syndrome: The clinical findings and treatments. Acta Paediatr Jpn 1996;38:84–90.
27.
Osterziel KJ, Strohm O, Schuler J, Friedrich M, Hanlein D, Willenbrock R, Anker SD, Poole-Wilson PA, Ranke MB, Dietz R: Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998;351:1233–1237.
28.
Thomas BC, Stanhope R: Long-term treatment with growth hormone in Noonan’s syndrome. Acta Paediatr 1993;82:853–855.
29.
De Schepper J, Otten BJ, Francois I, Bourguignon J-P, Craen M, van der Burgt I, Massa GC: Growth hormone therapy in pre-pubertal children with Noonan syndrome – first year growth response and comparison with Turner syndrome. Acta Paediatr 1997;86:943–946.
30.
Municchi G, Pasquino AM, Pucarelli I, Cianfarani S, Passeri F: Growth hormone treatment in Noonan syndrome: Report of four cases who reached final height. Horm Res 1995;44:164–167.
31.
Cotterill AM: Effectiveness of growth hormone therapy in Noonan syndrome; in Hindmarsh PC (ed): Current Indications for Growth Hormone Therapy. Basel, Karger, 1999, pp 118–127.
32.
Macfarlane CE, Brown DC, Brady AF, Johnston LB, Patton MA, Dunger DB, Savage MO, Kelnar CJH: Growth hormone therapy and growth in children with Noonan’s syndrome: Results of three years follow-up (abstract 373). Horm Res 1997;48(suppl 2):72.
33.
Freeman JV, Cole TJ, Chinn S, Jones PRM, White EM, Preece MA: Cross-sectional stature and weight reference curves for the UK, 1990. Arch Dis Child 1995;73:17–24.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.